Spectral Medical Inc., formerly Spectral Diagnostics Inc., is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents. The Company develops biochemical markers for the clinical syndrome known as septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. The Company develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies through non-exclusive license and supply agreements.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:DIAGF
- CUSIP: N/A
- Web: www.spectraldx.com/
- Trailing P/E Ratio:
- Foreward P/E Ratio: -5.95
- P/E Growth:
- Net Margins: -102.23%
- Return on Equity: -70.21%
- Return on Assets: -58.65%
Frequently Asked Questions for Spectral Medical (OTCMKTS:DIAGF)
What is Spectral Medical's stock symbol?
Spectral Medical trades on the OTCMKTS under the ticker symbol "DIAGF."
Who are some of Spectral Medical's key competitors?
Some companies that are related to Spectral Medical include Lundin Petrolm (LNDNY), Banco Popolare (BPSAY), DAILY MAIL&GEN TST SPON (DMTGY), African Barrick Gold Ltd (ABGLY), Solvay S.A. (SVYZY), Tencent Holding (TCEHY), Nestle SA (NSRGY), Cable & Wireless Communications Plc (CWIXF), L'Oreal SA (LRLCY), Naspers (NPSNY), Softbank Corp. (SFTBY), Volkswagen AG (VLKAY), Reckitt Benckiser Group PLC (RBGLY), National Australia Bank (NABZY), Bayerische Motoren Werke AG (BAMXF), Intesa Sanpaolo SpA (ISNPY), Glencore International PLC, St. Helier (GLCNF) and Glencore PLC (GLNCY).
Who are Spectral Medical's key executives?
Spectral Medical's management team includes the folowing people:
- Anthony P. Bihl III, Chairman of the Board
- Paul M. Walker M.D., Ph.D., President, Chief Executive Officer, Director
- Anthony Businskas, Chief Financial Officer, Executive Vice President, Corporate Secretary
- Gualitiero Guadagni, Vice President - Sales and Marketing
- Debra M. Foster RN, Vice President - Clinical Development
- Masayuki Kaneko, Director
- William Charles Stevens, Director
- Guillermo A. Herrera, Independent Director
How do I buy Spectral Medical stock?
Shares of Spectral Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectral Medical's stock price today?
MarketBeat Community Rating for Spectral Medical (OTCMKTS DIAGF)MarketBeat's community ratings are surveys of what our community members think about Spectral Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Spectral Medical stock can currently be purchased for approximately $0.36.
Consensus Ratings for Spectral Medical (OTCMKTS:DIAGF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Spectral Medical (OTCMKTS:DIAGF)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Spectral Medical (OTCMKTS:DIAGF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Spectral Medical (OTCMKTS:DIAGF)
Current Year EPS Consensus Estimate: $-0.060 EPS
Next Year EPS Consensus Estimate: $-0.060 EPS
Dividend History for Spectral Medical (OTCMKTS:DIAGF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Spectral Medical (OTCMKTS:DIAGF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Spectral Medical (OTCMKTS:DIAGF)
Latest Headlines for Spectral Medical (OTCMKTS:DIAGF)
No headlines for this company have been tracked by MarketBeat.com
Spectral Medical (DIAGF) Chart for Friday, July, 21, 2017